Financial Times honors the firm for its work in the KanaVape CBD case and partner David Ziyambi for diversity leadership.
Latham’s life sciences licensing group brings market-leading experience to structuring and negotiating the industry’s most transformative strategic partnerships, joint ventures, and other licensing agreements.
We draw on deep industry experience and technical knowledge to advise life sciences companies and their investors on the full range of technology-based commercial transactions. Many lawyers on our team hold advanced scientific and business degrees, are qualified to practice before the US Patent and Trademark Office, and have held legal and scientific positions within high-profile life sciences companies.
Our team routinely advises on life sciences transactions that receive industry-wide accolades for their innovative approaches to identify, develop and commercialize cutting-edge products. We advise across the spectrum of life sciences transactions, from vendor agreements and intellectual property and technology licensing transactions, to complex strategic alliances and collaborations. We work collaboratively with clients to identify, conceptualize, and develop creative solutions to the thorniest business and legal issues that arise in the course of a complex life sciences transaction.